Clinical Drug Investigation

, Volume 33, Issue 1, pp 71–91 | Cite as


A Review of its Use in the Treatment of Adults and Children with Overactive Bladder Associated with Idiopathic or Neurogenic Detrusor Overactivity, and in Men with Lower Urinary Tract Symptoms
  • Kate McKeageEmail author
Adis Drug Evaluation


Propiverine is a well established antimuscarinic agent with a mixed mode of action in the treatment of symptoms associated with overactive bladder (OAB). As well as blocking muscarinic receptors in the detrusor muscle, the drug also inhibits cellular calcium influx, thereby diminishing muscle spasm. In patients with symptoms of OAB resulting from idiopathic detrusor overactivity (IDO) or neurogenic detrusor overactivity (NDO), propiverine demonstrated dose-dependent efficacy and tolerability, with adverse events consistent with those associated with all antimuscarinic agents. In adults with IDO, propiverine demonstrated similar efficacy to that of other antimuscarinic agents (including solifenacin, tolterodine, oxybutynin and imidafenacin) and, in adults with NDO, propiverine and oxybutynin demonstrated similar efficacy. Propiverine was generally well tolerated in these patient populations, with a lower incidence of dry mouth than that associated with oxybutynin. In men with lower urinary tract symptoms (LUTS), and in whom the presence of benign prostatic enlargement (BPE) was implicated, propiverine administered as add-on therapy to an α1-adrenoceptor antagonist demonstrated similar or superior efficacy to that achieved with an α1-adrenoceptor antagonist alone, and combination therapy was particularly effective in patients with urinary storage symptoms. Combination therapy was generally well tolerated, but was associated with a higher incidence of adverse events than an α1-adrenoceptor antagonist alone. In children and adolescents with IDO/OAB or NDO, propiverine was generally more effective and better tolerated than oxybutynin. In conclusion, propiverine provides a valuable option for the treatment of adults and children with OAB associated with IDO or NDO, and in men with storage LUTS.


Lower Urinary Tract Symptom Detrusor Overactivity Oxybutynin International Prostate Symptom Score Tamsulosin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.


  1. 1.
    Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78.PubMedCrossRefGoogle Scholar
  2. 2.
    Chapple C, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49(4):651–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Oelke M, Baard J, Wijkstra H, et al. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol. 2008;54(2):419–26.PubMedCrossRefGoogle Scholar
  4. 4.
    Cheung WW, Blank W, Borawski D, et al. Prevalence of overactive bladder, its under-diagnosis, and risk factors in a male urologic veterans population. Int J Med Sci. 2010;7(6):391–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.PubMedGoogle Scholar
  6. 6.
    Temml C, Heidler S, Ponholzer A, et al. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol. 2005;48(4):622–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Chung JM, Lee SD, Kang DI, et al. Prevalence and associated factors of overactive bladder in Korean children 5–13 years old: a nationwide multicentre study. Urology. 2009;73(1):63–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Kajiwara M, Inoue K, Kato M, et al. Nocturnal eneuresis and overactive bladder in children: an epidemiological study. Urology. 2006;13(1):36–41.Google Scholar
  9. 9.
    Stöhrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009;56(1):81–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173(4):1256–61.PubMedCrossRefGoogle Scholar
  11. 11.
    Lucas MG, Bosch JLHR, Cruz FR, et al. European Association of Urology. Guidelines on urinary incontinence (online). Available from URL: [Accessed 2012 Sep 6].
  12. 12.
    Yamaguchi O, Nishizawa O, Takeda M, et al. Clinical guidelines for overactive bladder. Int J Urol. 2009;16(2):126–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Madersbacher H, Mürtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol. 2001;19(5):324–35.PubMedCrossRefGoogle Scholar
  14. 14.
    Wuest M, Hecht J, Christ T, et al. Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. Br J Pharmacol. 2005;145(5):608–19.PubMedCrossRefGoogle Scholar
  15. 15.
    Wuest M, Weiss A, Waelbroeck M, et al. Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn-Schmied Arch Pharmacol. 2006;374(2):87–97.CrossRefGoogle Scholar
  16. 16.
    Yamada S, Ito Y, Taki Y, et al. The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics. Drug Metab Dispos. 2010;38(8):1314–21.PubMedCrossRefGoogle Scholar
  17. 17.
    Uchida S, Kurosawa S, Fujino Oki T, et al. Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain. Life Sci. 2007;80(26):2454–60.PubMedCrossRefGoogle Scholar
  18. 18.
    Propping S, Braeter M, Grimm M-O, et al. Anticholinergic effects of cis- and trans-isomers of two metabolites of propiverine. Naunyn-Schmied Arch Pharmacol. 2010;381(4):329–38.CrossRefGoogle Scholar
  19. 19.
    Wuest M, Eichhorn B, Braeter M, et al. Muscarinic receptor expression and receptor-mediated detrusor contraction: comparison of juvenile and adult porcine tissue. Pflugers Arch. 2008;456(2):349–58.PubMedCrossRefGoogle Scholar
  20. 20.
    Wuest M, Witte LP, Michel-Reher MB, et al. The muscarinic receptor antagonist propiverine exhibits α1-adrenoceptor antagonism in human prostate and porcine trigonum. World J Urol. 2011;29(2):149–55.PubMedCrossRefGoogle Scholar
  21. 21.
    Moon HS, Lee JW, ParK SY, et al. Oxybutynin and propiverine suppress adenosine triphosphate-induced bladder overactivity other than through antimuscarinic mechanisms. Urology. 2010;76(2):509. (e8–12).PubMedCrossRefGoogle Scholar
  22. 22.
    Scheepe JR, van den Hoek J, Jünemann KP, et al. A standardised mini pig model for in vivo investigations of anticholinergic effects on bladder function and salivation. Pharmacol Res. 2007;55(5):450–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Christ T, Wettwer E, Wuest M, et al. Electrophysiological profile of propiverine: relationship to cardiac risk. Naunyn-Schmied Arch Pharmacol. 2008;376(6):431–40.CrossRefGoogle Scholar
  24. 24.
    Donath F, Braeter M, Feustel C. The influence of propiverine hydrochloride on cardiac repolarization in healthy women and cardiac male patients. Int J Clin Pharmacol Ther. 2011;49(6):353–65.PubMedGoogle Scholar
  25. 25.
    Haustein KO, Huller G. On the pharmacokinetics and metabolism of propiverine in man. Eur J Drug Metab Pharmacokinet. 1988;13(2):81–90.PubMedCrossRefGoogle Scholar
  26. 26.
    May K, Westphal K, Giessmann T, et al. Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: influence of dosage forms and circadian-time rhythms. J Clin Pharmacol. 2008;48(5):570–9.PubMedCrossRefGoogle Scholar
  27. 27.
    May K, Giessmann T, Wegner D, et al. Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination. Eur J Clin Pharmacol. 2008;64(11):1085–92.PubMedCrossRefGoogle Scholar
  28. 28.
    Medicines Compendium UK. Detrunorm 15 mg tablets. Summary of product characteristics (online). Available from URL: [Accessed 2012 August 6].
  29. 29.
    Medicines and Healthcare products Regulatory Agency. Public assessment report: Mictonorm XL 30 mg modified release capsules, Proprinorm XL 30 mg modified release capsules (online). Available from URL: [Accessed 2012 August 6].
  30. 30.
    Siegmund W, Siegert J, Richter K, et al. Influence of a fat-rich meal on bioavailability of extended-release and immediate-release propiverine. J Clin Pharmacol. 2012;52(5):681–90.PubMedCrossRefGoogle Scholar
  31. 31.
    Huang M, Tian Y, Zhang Z, et al. Determination of propiverine hydrochloride in human plasma by high performance liquid chromatography-tandem mass spectrometry: application to the pharmacokinetic study of a sustained release formulation. Arzneimittelforschung. 2011;61(9):494–501.PubMedCrossRefGoogle Scholar
  32. 32.
    Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, et al. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos. 2005;33(12):1859–66.PubMedGoogle Scholar
  33. 33.
    Siegmund W, Sillen U, Lackgren G, et al. Pharmacokinetics and pharmacodynamics of propiverine in children aged between 5 and 10 years with symptoms of overactive bladder. Clin Pharmacokinet. 2010;49(5):335–42.PubMedCrossRefGoogle Scholar
  34. 34.
    Schulte-Baukloh H, Mürtz G, Heine G, et al. Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study. J Pediatr Urol. 2012;8(4):386–92.PubMedCrossRefGoogle Scholar
  35. 35.
    Mazur D, Wehnert J, Dorschner W, et al. Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicentre dose-optimizing study. Scan J Urol Nephrol. 1995;29(3):289–94.CrossRefGoogle Scholar
  36. 36.
    Gotoh M, Yokoyama O, Nishizawa O, et al. Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial. Int J Urol. 2011;18(5):365–73.PubMedCrossRefGoogle Scholar
  37. 37.
    Dorschner W, Stolzenburg JU, Griebenow R, et al. Efficacy and cardiac safety of propiverine in elderly patients: a double-blind, placebo-controlled clinical study. Eur Urol. 2000;37(6):702–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Jünemann KP, Hessdorfer E, Unamba-Oparah I, et al. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urol Int. 2006;77(4):334–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Lee K-S, Lee HW, Choo M-S, et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the ‘propiverine study on overactive bladder including urgency data’. BJU Int. 2010;105(11):1565–70.PubMedCrossRefGoogle Scholar
  40. 40.
    Homma Y, Yamaguchi O, Group IS. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol. 2009;16(5):499–506.PubMedCrossRefGoogle Scholar
  41. 41.
    Yamaguchi O, Marui E, Kakizaki H, et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007;100(3):579–87.PubMedCrossRefGoogle Scholar
  42. 42.
    Leng J, Wan B, Du C, et al. Randomized clinical trial evaluating safety and efficacy of propiverine ER 30 mg and tolterodine ER 4 mg in the treatment of overactive bladder (abstract no. 338). International Continence Society Annual Meeting. Beijing; 2012 Oct 15–19.Google Scholar
  43. 43.
    Abrams P, Cardozo L, Chapple C, et al. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol. 2006;13(6):692–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Jünemann K-P, Halaska M, Rittstein T, et al. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol. 2005;48(3):478–82.PubMedCrossRefGoogle Scholar
  45. 45.
    Madersbacher H, Halaska M, Voigt R, et al. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int. 1999;84(6):646–51.PubMedCrossRefGoogle Scholar
  46. 46.
    Wada N, Watanabe M, Kita M, et al. Efficacy and safety of propiverine and solifenacin for the treatment of female patients with overactive bladder: a crossover study. LUTS. 2011;3(1):36–42.Google Scholar
  47. 47.
    Masumori N, Miyamoto S, Tsukamoto T, et al. The efficacy and safety of propiverine hydrochloride in patients with overactive bladder symptoms who poorly responded to previous anticholinergic agents. Adv Urol. 2011. doi: 10.1155/2011/714978.
  48. 48.
    Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder syndrome: overactive bladder symptom score. Urology. 2006;68(2):318–23.PubMedCrossRefGoogle Scholar
  49. 49.
    Marschall-Kehrel D, Feustel C, Persson de Geeter C, et al. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. Eur Urol. 2009;55(3):729–36.PubMedCrossRefGoogle Scholar
  50. 50.
    Kessler-Zumpe PL, Murgas S, Neumann G, et al. Therapy of overactive bladder with propiverine ER. Results of a non-interventional study with propiverine retard formulation and comparison to clinical studies (in German). Urologe. 2009;48:1346–51.PubMedCrossRefGoogle Scholar
  51. 51.
    Alloussi S, Schönberger B, Mürtz G, et al. Treatment of the urge-syndrome with propiverine in therapeutic practice: tolerability and efficacy in 4390 patients (in German). Urologe B. 2000;40:367–73.CrossRefGoogle Scholar
  52. 52.
    Stöhrer M, Madersbacher H, Richter R, et al. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia: a double-blind, placebo-controlled clinical trial. Spinal Cord. 1999;37:196–200.PubMedCrossRefGoogle Scholar
  53. 53.
    Takayasu H, Ueno A, Tsuchida S, et al. Clinical evaluation of propiverine hydrochloride (P4) against pollakisuria and urinary incontinence: a multicenter, placebo-controlled double-blind study (in Japanese). Prog Med. 1990;153:459–71.Google Scholar
  54. 54.
    Stöhrer M, Murtz G, Kramer G, et al. Efficacy and tolerability of propiverine hydrochloride extended release compared to immediate release in patients with neurogenic detrusor overactivity (abstract no. 448). International Continence Society Annual Meeting. San Francisco; 2009 Sep 29 –2009 Oct 3.Google Scholar
  55. 55.
    Stöhrer M, Mürtz G, Kramer G, et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity: results of a randomized, double-blind, multicenter clinical study. Eur Urol. 2007;51(1):235–42.PubMedCrossRefGoogle Scholar
  56. 56.
    Bae JH, Kim SO, Yoo ES, et al. Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: a prospective, randomized, single-blinded and multicenter clinical trial. Korean J Urol. 2011;52(4):274–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol. 2005;174(4 Pt 1):1334–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Nishizawa O, Yamaguchi O, Takeda M, et al. Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. LUTS. 2011;3:29–35.Google Scholar
  59. 59.
    Saito H, Yamada T, Oshima H, et al. A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence (in Japanese). Jpn J Urol Surg. 1999;12:525–36.Google Scholar
  60. 60.
    Seo KI, Hong SZ, Lee JB. The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms (in Korean). Korean J Urol. 2009;50(11):1078–82.CrossRefGoogle Scholar
  61. 61.
    Yokoyama T, Uematsu K, Watanabe T, et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol Nephrol. 2009;43(4):307–14.PubMedCrossRefGoogle Scholar
  62. 62.
    Matsukawa Y, Hattori R, Mazima T, et al. Is combination therapy with an anticholinergic agent and an alpha1-adrenoceptor antagonist useful as first-line treatment in patients with benign prostatic hyperplasia complicated by overactive bladder? A randomized, prospective, comparative study using a urodynamic study (abstract no. 753). 27th Congress of the European Association of Urology. Paris; 2012 Feb 24–28.Google Scholar
  63. 63.
    Kamimura N, Hatakeyama S, Kudo S, et al. Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy (in Japanese). Hinyokika Kiyo. 2011;57:71–6.PubMedGoogle Scholar
  64. 64.
    Oelke M, Murgas S, Baumann I, et al. Efficacy of propiverine ER with or without alpha-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study. World J Urol. 2011;29(2):217–23.PubMedCrossRefGoogle Scholar
  65. 65.
    Kim WJ, Lee D-G, Lee SW, et al. Efficacy and safety of propiverine in children with overactive bladder. Korean J Urol. 2012;53(4):275–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Alloussi S, Mürtz G, Braun R, et al. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: results of a multicentre observational cohort study. BJU Int. 2010;106(4):550–6.PubMedCrossRefGoogle Scholar
  67. 67.
    Schulte-Baukloh H, Mürtz G, Henne T, et al. Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis. BJU Int. 2006;97(2):355–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Grigoleit U, Mürtz G, Laschke S, et al. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity: a retrospective study. Eur Urol. 2006;49(6):1114–20.PubMedCrossRefGoogle Scholar
  69. 69.
    Madersbacher H, Mürtz G, Alloussi S, et al. Propiverine vs. oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. BJU Int. 2009;103(6):776–81.PubMedCrossRefGoogle Scholar
  70. 70.
    Apogepha. Mictonetten® 5 mg coated tablets. Product information leaflet (online). Available from URL: [Accessed 2012 Nov 19].
  71. 71.
    Noguchi K, Masuda M, Noguchi S, et al. Longterm administration study of propiverine hydrochloride (BUP-4® tablets) in pollakiuria and urinary incontinence (in Japanese). Hinyokika Kiyo. 1998;44:687–93.PubMedGoogle Scholar
  72. 72.
    Medicines and Healthcare products Regulatory Agency. Public assessment report: Mictonorm XL 45 mg modified release capsules (propiverine hydrochloride) (online). Available from URL: [Accessed 2012 August 6].
  73. 73.
    Medicines Compendium UK. Detrunorm XL 30 mg modified release capsules. Summary of product characteristics (online). Available from URL: [Accessed 2012 Nov 14].
  74. 74.
    Schröder A, Thüroff JW. New strategies for medical management of overactive bladder in children. Curr Opin Urol. 2010;20(4):313–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Oelke M, Bachmann A, Descazeaud A, et al. European association of urology. Guidelines of the management of male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). Available from URL: [Accessed 2012 Sep 6].
  76. 76.
    Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–62.PubMedCrossRefGoogle Scholar
  77. 77.
    Asimakopoulos AD, Cerruto MA, Del Popolo G, et al. An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity. Urol Int. 2012;89(3):259–69.PubMedCrossRefGoogle Scholar
  78. 78.
    Blake-James BT, Rashidian A, Ikeda Y, et al. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int. 2006;99(1):85–96.PubMedCrossRefGoogle Scholar
  79. 79.
    Paquette A, Gou P, Tannenbaum C, et al. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc. 2011;59(7):1332–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Uchiyama T, Sakakibara R, Liu Z, et al. The effects of anticholinergic drugs for overactive bladder on cognitive impairment, mental dysfunction and motor dysfunction in patients with neurological disease (abstract no. 245). International Continence Society Annual Meeting. Montreal; 2005 Aug 28–2005 Sep 2.Google Scholar
  81. 81.
    Sakakibara R, Ogata T, Uchiyama T, et al. How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist (letter). J Am Geriatr Soc. 2009;57(8):1515–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Kluge A, Vohs K, Siegert J, et al. Effect of propiverine on psychomotor performance (abstract no. P319). International Continence Society Annual Meeting. Athens; 1996 Aug 27–30.Google Scholar
  83. 83.
    Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl.):506–14.Google Scholar
  84. 84.
    Cardozo L, Thorpe A, Warner J, et al. The cost-effectiveness of solifenacin vs. fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int. 2000;106(4):506–14.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2012

Authors and Affiliations

  1. 1.AdisNorth ShoreNew Zealand

Personalised recommendations